Clinical trials: Type II Diabetes Mellitus
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.
- Trial name
- NCT01520753
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 50
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.
- Trial name
- NCT01204775
- Testing
- Saxagliptin, Metformin IR, Metformin (Active Rescue)
- Where
- 16 sites in United States, Russia and 2 more
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Diabetes Mellitus Type 2
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and…
- Trial name
- NCT01018173
- Testing
- taspoglutide
- Where
- 288 sites in United States, Australia and 23 more
- Volunteers
- 2,118 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin…
- Trial name
- NCT05102071
- Testing
- empagliflozin, metformin, sulfonylurea
- Where
- United States
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their…
- Trial name
- NCT03987802
- Testing
- Faster-acting insulin aspart
- Where
- 36 sites in India
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human
This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.
- Trial name
- NCT06495931
- Testing
- HRS-1780 tablets, HR20033 tablets, HRS-7535 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects
This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.
- Trial name
- NCT06422039
- Testing
- HRS-7535(D) Tablets, HRS-7535(C) Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes Mellitus, Type 2
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341312
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 2, Bariatric Surgery
Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel Endoscopic Magnetic Metabolic Interventional Therapy
English, Hindi and Gujarati
- Trial name
- 2025/08/EMMIT (NCT07350967)
- Testing
- Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion
- Where
- India
- Volunteers
- 5 people
- Sponsor
- iIDEAS Group Holdings Limited
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Diabetes, Diabetes Mellitus, Type 2
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on…
- Trial name
- BOOST™ (NCT01059812)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 46 sites in Hong Kong, Japan and 3 more
- Volunteers
- 424 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine
The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor.
- Trial name
- VIEW-Iran (NCT03888157)
- Testing
- Liraglutide
- Where
- 16 sites in Iran
- Volunteers
- 839 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
GALLANT 8 Tesaglitazar Add-on to Metformin
This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to metformin in patients with type 2 diabetes, not adequately controlled…
- Trial name
- NCT00251953
- Testing
- Tesaglitazar, Metformin
- Where
- 107 sites in Australia, Canada and 9 more
- Volunteers
- 555 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Purpose of this study is to evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination with GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic…
- Trial name
- NCT02291874
- Testing
- Ipragliflozin
- Where
- 6 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
This study evaluate DRBP108 in the treatment of type 2 diabetes mellitus. The patients were randomly allocated to four groups: 50 mg, 100 mg, 200 mg and placebo group.
- Trial name
- NCT04124484
- Where
- China
- Volunteers
- 276 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.